Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 1;18:143. doi: 10.1186/s12882-017-0565-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Distribution of forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and estimated glomerular filtration rate (eGFR) by disease status. The figure shows the 25th, 50th (Median) and 75th percentile of the distribution of forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and estimated glomerular filtration rate (eGFR) (vertical lines on each box). ‘Whiskers’ on each box indicate values at 1.5 times the interquartile range from the median and dots indicate the more extreme values, including the maximum and minimum of the distribution. MS, metabolic syndrome; DM, diabetes mellitus. a Distribution of FEV1 by disease status in Nanjing survey; (b) Distribution of FEV1 by disease status in Crossroads study; (c) Distribution of FVC by disease status in Nanjing survey; (d) Distribution of FVC by disease status in Crossroads study; (e) Distribution of FEV1% predicted value by disease status in Nanjing survey; (f) Distribution of FEV1% predicted value by disease status in Crossroads study; (g) Distribution of FVC% predicted value by disease status in Nanjing survey; (h) Distribution of FVC% predicted value by disease status in Crossroads study; (i) Distribution of eGFR by disease status in Nanjing survey; (j) Distribution of eGFR by disease status in Crossroads study